Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Seagen Inc
(NQ:
SGEN
)
228.74
UNCHANGED
Last Price
Updated: 4:00 PM EST, Dec 13, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Seagen Inc
< Previous
1
2
3
4
5
Next >
Seagen Reports First Quarter 2022 Financial Results
April 28, 2022
From
Seagen Inc.
Via
Business Wire
Seagen to Highlight Data from Expanding Oncology Portfolio at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
April 28, 2022
From
Seagen Inc.
Via
Business Wire
Seagen Announces Plans to Expand Pacific Northwest Biomanufacturing Capacity to Support Growing Portfolio of Transformative Cancer Medicines
April 20, 2022
From
Seagen Inc.
Via
Business Wire
Seagen Publishes Inaugural Corporate Responsibility Report
December 07, 2021
SOURCE: Seagen
Via
3BL Media
Topics
Emissions
Exposures
Product Safety
European Commission Approves PADCEV™ (enfortumab vedotin) for Locally Advanced or Metastatic Urothelial Cancer
April 13, 2022
From
Seagen Inc.
Via
Business Wire
Seagen Announces Jury Award in Patent Infringement Case Against Daiichi Sankyo
April 08, 2022
From
Seagen Inc.
Via
Business Wire
Seagen to Highlight Preclinical Data for Enfortumab Vedotin and Two Novel Antibody-Drug Conjugates at AACR Annual Meeting
April 08, 2022
From
Seagen Inc.
Via
Business Wire
Seagen to Host Conference Call and Webcast Discussion of First Quarter 2022 Financial Results on April 28, 2022
April 07, 2022
From
Seagen Inc.
Via
Business Wire
Seagen and Sanofi Announce Collaboration to Develop and Commercialize Multiple Novel Antibody-Drug Conjugates
March 16, 2022
From
Seagen Inc.
Via
Business Wire
Astellas and Seagen Announce CHMP Confirms Positive Opinion for PADCEV™ (enfortumab vedotin) in Locally Advanced or Metastatic Urothelial Cancer
February 28, 2022
From
Seagen Inc.
Via
Business Wire
Seagen and Genmab Present First Data on Tisotumab Vedotin (TIVDAK®) in Patients with Head and Neck Squamous Cell Carcinoma
February 24, 2022
From
Seagen Inc.
Via
Business Wire
Genmab and Seagen Present First Data on Tisotumab Vedotin (TIVDAK®) in Patients with Head and Neck Squamous Cell Carcinoma
February 24, 2022
From
Genmab A/S
Via
Business Wire
Seagen and Astellas Announce Initial Results of PADCEV® (enfortumab vedotin-ejfv) in Patients With Muscle-Invasive Bladder Cancer Not Eligible for Cisplatin Chemotherapy
February 14, 2022
From
Seagen Inc.
Via
Business Wire
Seagen Reports Fourth Quarter and Full Year 2021 Financial Results
February 09, 2022
From
Seagen Inc.
Via
Business Wire
Seagen to Present at the 11th Annual SVB Leerink Global Healthcare Conference
February 08, 2022
From
Seagen Inc.
Via
Business Wire
ADCETRIS® Combination Significantly Improves Overall Survival in Newly Diagnosed Patients with Advanced Hodgkin Lymphoma
February 03, 2022
From
Seagen Inc.
Via
Business Wire
Groundbreaking Clinical Trials Accelerating New Treatment Options for Pancreatic Cancer
February 02, 2022
Palm Beach, FL – February 2, 2022 – FinancialNewsMedia.com News Commentary – In the battle against pancreatic cancer, new and innovative clinical trials have become extremely critical. These trials...
Via
FinancialNewsMedia
Seagen Appoints Lee Heeson as Executive Vice President, Commercial International
February 01, 2022
From
Seagen Inc.
Via
Business Wire
Seagen Reports Data From SEA-CD40 in Combination With Other Therapies in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI)
January 18, 2022
From
Seagen Inc.
Via
Business Wire
Seagen to Host Conference Call and Webcast Discussion of Fourth Quarter and Full Year 2021 Financial Results on February 9, 2022
January 18, 2022
From
Seagen Inc.
Via
Business Wire
Seagen to Present at the J.P. Morgan Healthcare Conference
December 20, 2021
From
Seagen Inc.
Via
Business Wire
Astellas and Seagen Receive Positive CHMP Opinion for PADCEV™ (enfortumab vedotin) in Locally Advanced or Metastatic Urothelial Cancer
December 17, 2021
From
Seagen Inc.
Via
Business Wire
Seagen Announces Preliminary Results from Phase 2 Clinical Trial of ADCETRIS® (brentuximab vedotin) in Novel Combination of Agents for Patients with Advanced Stage Classical Hodgkin Lymphoma
December 12, 2021
From
Seagen Inc.
Via
Business Wire
Seagen Announces Updated Results from Pivotal HER2CLIMB Trial Evaluating TUKYSA® (tucatinib) in Patients with HER2-Positive Breast Cancer with Brain Metastases
December 08, 2021
From
Seagen Inc.
Via
Business Wire
Seagen to Highlight New Data in Advanced Breast Cancer at 2021 San Antonio Breast Cancer Symposium
November 19, 2021
From
Seagen, Inc.
Via
Business Wire
Seagen to Highlight Two Novel Antibody-Drug Conjugates (ADCs) at the SITC 36th Annual Meeting
November 09, 2021
From
Seagen Inc.
Via
Business Wire
Seagen to Highlight Multiple ADCETRIS® (brentuximab vedotin) Data Presentations at the Upcoming 2021 American Society of Hematology (ASH) Annual Meeting
November 04, 2021
From
Seagen Inc.
Via
Business Wire
Seagen Reports Third Quarter 2021 Financial Results
October 28, 2021
From
Seagen Inc.
Via
Business Wire
Seagen and Astellas Complete Enrollment in EV-103 Trial Cohort K Combining PADCEV® (enfortumab vedotin-ejfv) With Pembrolizumab as First-Line Treatment for Advanced Urothelial Cancer
October 12, 2021
From
Seagen Inc.
Via
Business Wire
Seagen to Host Conference Call and Webcast Discussion of Third Quarter 2021 Financial Results on October 28, 2021
October 07, 2021
From
Seagen Inc.
Via
Business Wire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.